American Brivision (Holding) Corp. Announces Stock Split of Its Issued and Outstanding Shares of Common Stock at a Ratio of 1-For-3.141

Loading...
Loading...

GOSHEN, NY / ACCESSWIRE / April 8, 2016 / American BriVision (Holding) Corp. ABVC (the "Company"), a biotechnology company focused on the development of new drugs and innovative medical devices to fulfill unmet medical needs, today said that on April 8, 2016 8:00 am Eastern Standard Time (the "Effective Time"), the Company effects a forward stock split of its issued and outstanding shares of common stock, par value $0.001 per share (the "Common Stock"), at a ratio of 1-for-3.141 (the "Stock Split"). The Stock Split was approved by the Company's board of directors and a majority shareholder of the Company's issued and outstanding shares of Common Stock.

Upon effectiveness of the Stock Split, every share of the Company's issued and outstanding Common Stock is automatically converted into 3.141 shares, without any change in par value per share and without any further action by the Corporation or the holder thereof, subject to the treatment of fractional share interests as described herein below. The Stock Split is applied to all shares of issued and outstanding Common Stock immediately prior to the Effective Time. No fractional shares will be issued as a result of the Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will be entitled to rounding up their fractional shares to the nearest whole number.

The Company's common stock will begin trading on the OTCQB on a split-adjusted commencing on the Effective Time. The trading symbol for the common stock will remain "ABVC" except that a "D" may be appended to the ticker symbol for approximately 20 trading days following the effectiveness of the Stock Split on the market.

About American BriVision (Holding) Corp.:

Through its wholly owned subsidiary, American BriVision Corporation, which was incorporated in 2015 in the State of Delaware, the Company is focused on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center ("MSKCC") and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept ("POC"), out-license to international pharmaceutical companies, and exploit global markets.

Safe Harbor Statement

This news release may contain "forward-looking" statements. These forward-looking statements are only predictions and are subject to certain risks, uncertainties and assumptions that could cause actual results to differ from those in the forward looking-statements. Potential risks and uncertainties include such factors as uncertainty of consumer demand for the Company's products, as well as additional risks and uncertainties that are identified and described in Company's SEC reports. Actual results may differ materially from the forward-looking statements in this press release. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company does not undertake, and it specifically disclaims, any obligation to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement.

Contacts:

Loading...
Loading...

American BriVision (Holding) Corporation
Kira Huang
CFO
kira.huang@ambrivis.com
+886-958-680326

SOURCE: American BriVision (Holding) Corporation

Loading...
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...